从中美跨境医疗投资的视角谈中国人如何在美国做风投

哈佛大学中国学生学者联合会 2017-03-14 02:01:46 阅读(0) 评论()

声明：本文由入驻搜狐公众平台的作者撰写，除搜狐官方账号外，观点仅代表作者本人，不代表搜狐立场。举报

Time: March 17th 2:15 pm
location: RSVP for detail locations

　　"Read More/阅读原文" to RSVP

　　or scan the QR code to join the event group

　　在白人主导的美国风投圈中，中国投资人如何带入不同的视角和资源，获取北美本土最优秀企业投资的入场券？

　　中美间的跨境投资又究竟有如何的门道？

　　美国医疗最先进的生物技术“嫁接”回国有什么的机遇和风向？

　　Guest Speakers

　　Wei Li, PhD

Founding Partner of Wuxi Healthcare Ventures
Ex-Executive Partner, Fidelity Biosciences & Fidelity Growth Partner Asia
Co-Founder of Innovent Bio
Ex-Senior Manager, Vertex Pharmaceuticals
PhD in Biochemistry from Harvard; MBA from Kellogg

　　About Wuxi Healthcare Venture: Founded in 2011 and based in Cambridge, Wuxi Healthcare Ventures is a venture capital firm specializing in early stage and growth capital investments with a focus on medical devices, digital health, diagnostics, and pharmaceuticals. The fund manages asset of over 300mm USD and star portfolios including 23 and Me, Agios, Juno Therapeutics, Foundation Medicine, Twist Bioscience and etc. Wuxi Venture is one of the leading Chinese investors inside the Boston life science hub.

　　Chong Xu is an Associate at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

　　Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

　　About F-prime: Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. Under the flag of Fidelity Investment, F-Prime Capital invests in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors) in the US and Europe.

　　主办：

　　HCSSA

　　协办：

　　HMS CSSA

　　HLS CLA

　　MIT Sloan GCC